Navigation Links
Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimer's Biomarker Assay
Date:2/25/2009

ROCKVILLE, Md., Feb. 25 /PRNewswire-USNewswire/ -- Adlyfe, a private company developing novel biomarkers and diagnostic tests for amyloid diseases, announced today that it has signed an agreement with Wyeth Pharmaceuticals, a division of Wyeth, to develop biomarker assays designed to measure levels of beta amyloid in the human brain. The companies will develop assays for specific beta amyloid targets for use in facilitating the development of treatments for Alzheimer's disease. The multiyear agreement included an upfront payment and specific future milestone payments. Further details of the agreement were not disclosed.

Chief Executive Officer Alan S. Rudolph, Ph.D., MBA said, "This agreement is a strong statement on the potential of Adlyfe's Pronucleon(TM) technology. This partnership will enable us to move faster in developing our assay, which could serve as an important tool in assessing the efficacy of amyloid-targeted therapies."

Burrill LLC served as financial advisor to Adlyfe in this transaction.

About Alzheimer's disease

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive deterioration together with declining activities of daily living and neuropsychiatric symptoms or behavioral changes. It is the most common type of dementia. As the disorder progresses, cognitive impairment extends to the domains of language, skilled movements, recognition, and those functions closely related to the frontal and temporal lobes of the brain. This pathological process consists principally of neuronal loss or atrophy, principally in the temporoparietal cortex but also in the frontal cortex, together with an inflammatory response to the deposition of amyloid plaques and neurofibrillary tangles. According to the NIH's National Institute on Aging, as many as 5.5 million Americans presently suffer from Alzheimer's disease.

Abou
'/>"/>

SOURCE Adlyfe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
2. Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline
3. Queens University Chooses Xceeds Ziplex(R) System for Translational Research
4. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
5. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
6. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
7. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
8. Personalized Medicine - The Genomic Revolution in Cardiac Care
9. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
10. U.S. Preventive Medicine Acquires Specialty Disease Management
11. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., SANDIEGO,Nov.25/PRNewswire-FirstCall/--NuVasi...dondevelopingproductsforminimallydisruptivesurgica...taconferencecallonMonday,November30,2009,at5:30p.m...issuesrelativetoreimbursementfortheCompany,sproduc...hortquestionandanswersession.Thedial-innumbersare1...
(Date:11/25/2009)..., NEWYORK,Nov.25/PRNewswire/--Reportlinker.coma...tscatalogue: ,, IntranasalDrugDelivery-USMarke...p0164267/Intranasal-Drug-Delivery---US-Market-Tren...rymarketiswitnessinganexpansionoftherapeuticapplic...cdrugstothedeliveryofsystemictherapeuticdrugs.Thef...
(Date:11/25/2009)..., MOUNTAINVIEW,Calif.,Nov.25/PRNewswire/-- Che...aldatafromtheCompany,sPROTECT-1(theProspectiveRand...fTraficet-EN(TM)(CCX282-B)inpatientswithmoderate-t...withafavorablesafetyandtolerabilityprofile.Thestud...ionofdiseaseseverityasdefinedasa70-pointdecreasein...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5OxySure 28R 29 Aids Student in School Respiratory Arrest 3A WFAA Channel 8 News 5835 1OxySure 28R 29 Aids Student in School Respiratory Arrest 3A WFAA Channel 8 News 5835 2OxySure 28R 29 Aids Student in School Respiratory Arrest 3A WFAA Channel 8 News 5835 3Burton Medicals New Diagnostic Examination Light the AIM LED Provides 10 Percent More Illumination and 10 Times Greater Lamp Life 5833 1Burton Medicals New Diagnostic Examination Light the AIM LED Provides 10 Percent More Illumination and 10 Times Greater Lamp Life 5833 2Rogan Delft Approves Matrox Xenia Series for Use With Zillion Suite 5831 1Rogan Delft Approves Matrox Xenia Series for Use With Zillion Suite 5831 2Rogan Delft Approves Matrox Xenia Series for Use With Zillion Suite 5831 3
...SynergEyes, Inc., the high Dk hybrid contact lens ... million in Series C financing to fund the develop...d contact lens products and to expand sales and ma...f Palo Alto, CA, led this round as well as SynergE...joined Series A and B investors: Alloy Ventures, D...
...e of Cardiology publishes positive ATLAS clinical ... Corporation (NYSE: BSX ) today announced that i...ration (FDA) the final modules of the Company,s Pr...TAXUS(R) Liberte(R) Atom(TM) Paclitaxel-Eluting Co... Paclitaxel-Eluting Coronary Stent System. If app...
Other Medicine Technology:SynergEyes, Inc. Raises $13.3 Million in 'Series C' Financing 2Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents 2Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents 3Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents 4Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents 5
(Date:11/25/2009)...ire/--WhenmostpeopleheartheacronymTMJ,theythinkoft...helptheyneed.TMJstandsfortheTemporal-MandibularJoi...ithyourskull(temporalbone). ,, Themostcommonsym...g,clickingorpoppingofthejaw.Butmanyothersymptomsca...igue,sleepdisturbances,irritability,alossinfocus,r...
(Date:11/25/2009)...MedicalInc.,aleadingmanufacturerofbreastMRIcoilsan...eadingedgeclinicalapplicationsonitsAegis(TM)medica...cietyofNorthAmerica(RSNA)annualmeetinginChicago,No...veragetheuniquehighqualityimagesgeneratedbySentine...magingmodalitiesformulti-parametricassessment. ,...
(Date:11/25/2009)...ayAreaAirQualityManagementDistrictisissuingtheseas... forThursday,November26,2009whichbansburningwood,m...andoutdoors. ,, "Cold,stillweatherwillcontribut...executiveofficeroftheAirDistrict."We,reaskingBayAr...llowcommunitymembersthisThanksgiving,andnottoburnw...
(Date:11/25/2009)... collaboration between UCLA engineers and physicia...illion Americans who suffer from peripheral arteri... arteries, peripheral arterial disease, or PAD, is...teries reduce blood flow to the limbs. The conditi...heart attack and stroke, and its progression can r...
(Date:11/25/2009)...tment clinics to resume Monday, Nov. 30 , ...09 -- Centegra Health System is continuing to offe...ur Centegra Primary Care (CPC) vaccination clinics...e clinics are at CPC sites in Huntley, Woodstock, ...ws: ,   From 4:30 to 7:30 p.m. Tuesday...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4
...ts , , FRIDAY, Nov. 21 (HealthDay News) -...at child,s risk of asthma, new research suggests. ...e the peak of winter virus season -- have almost a...Journal of Respiratory and Critical Care Medicine ...
... are not given adequate drug therapy. This is the ...dition of Deutsches rzteblatt International ( Dt...r et al. present the German results of this prospe...cardiovascular diseases and 10.8% only exhibited r...
...oration (NYSE: HUN ) today announced that its Fo...r Americans chosen by the American Cancer Society ... honor. Given annually, the,award is reserved for...or,personally contributed over $600 million to the...
...utual Life,Insurance Company (MassMutual) today an...ng Officers. , -- Roger W. Crandall, Co-Chie...Chief Investment Officer, will assume the position...Operating Officer,and join the company,s Board of ...
...Inc.,( http://www.cardiosolutionsinc.com ) has ann... Ph.D. to the position of Chief Surgical Officer. ...er for Aortic Surgery and Director of the,Marfan S...c. is developing its proprietary Percu-Pro(TM) Sys...
...ocated in,Pittsburgh PA, and a subsidiary of Draeg...ountering what it believes are unsubstantiated all...formerly Bacou-Dalloz USA) of a patent,infringemen... property rights, but,believes that this lawsuit i...
Other Medicine News:Health News:Autumn Babies More Prone to Asthma 2Health News:Autumn Babies More Prone to Asthma 3Health News:Jon M. Huntsman Receives American Cancer Society Medal of Honor 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 3Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 4Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 5Health News:Cardiosolutions Names Dr. Lars Svensson Chief Surgical Officer 2Health News:Draeger Counters What It Believes Are Unsubstantiated Allegations of Patent Infringement by Sperian 2
Basic modular VICTOR2 Multilabel Counter (3 technologies)
VICTOR2 V (5 technologies), manual model
VICTOR2 multilabel counter with stacker and robot loading
... 96-channel parallel detection of fluorescence, ab...l microtiter plates. Compact workstations and sys...ansport of microtiter plates with a throughput of ... switching required by numerous other systems to s...
Medicine Products: